Recursion Pharmaceuticals, drug discovery, has filed Amendment No 2 to Form S-1 Registration Statement on April 15, 2021 with the U.S. Securities and Exchange Commission to increase the proposed IPO size by offering 22 million shares, previously filed to offer 18 million shares.
The company plans to raise $374 billion by offering 22 million shares at a price range of $16 to $18. Assuming a successful IPO at the midpoint of the proposed range, the company expects a market capitalization of $3 billion.
The company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
The Salt Lake City, Utah-based company was founded in 2013 and booked $4 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq Global Select Market under the symbol “RXRX.” Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen & Company are underwriters of the IPO.
The company engages Wilson Sonsini Goodrich & Rosati PC as US Securities Counsel, and Ernst & Young LLP as Independent Auditor.
#ipo #Nasdaq #Recursion #drug #biology #science #technology
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
